Parkinson’s disease: A treatment guide

,; ,

Applied Evidence

Parkinson’s disease: A treatment guide

J Fam Pract. 2018 May;67(5):276-279,284-286

By

Jocelyn Young, DO

Michael Mendoza, MD, MPH, MS, FAAFP

By following this stepwise approach, you can confidently incorporate newer agents into your armamentarium with little or no consultation with subspecialists.

PDF Download

PRACTICE RECOMMENDATIONS

› Use carbidopa/levodopa as first-line treatment for most patients with Parkinson's disease. A

› Prescribe rasagiline or entacapone for the treatment of motor fluctuations secondary to dopaminergic therapies. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

From The Journal of Family Practice | 2018;67(5):276-279,284-286.

References

1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896-912.

2. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055-2066.

3. Todorova A, Jenner P, Chaudhuri K. Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Pract Neurol. 2014;14:310-322.

4. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583-1590.

5. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72:893-901.

6. Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007;64:666-672.

7. Pakpoor J, Noyce A, Goldacre R, et al. Viral hepatitis and Parkinson disease: a national record-linkage study. Neurology. 2017;88:1630-1633.

8. Hern T, Newton W. Does coffee protect against the development of Parkinson disease (PD)? J Fam Pract. 2000;49:685-686.

9. Zhang SM, Hernán MA, Chen H, et al. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59:1161-1169.

10. Rao G, Fisch L, Srinivasan S, et al. Does this patient have Parkinson disease? JAMA. 2003;289:347-353.

11. Suchowersky O, Reich S, Perlmutter J, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:968-975.

12. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78:36-42.

13. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64:533-535.

14. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.

15. Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566-576.

16. National Institute for Heath and Care Excellence. Parkinson’s disease in adults. NICE guideline NG 71. 2017. Available at: https://www.nice.org.uk/guidance/ng71. Accessed March 27, 2018.

18. Lang AE, Marras C. Initiating dopaminergic treatment in Parkinson’s disease. Lancet. 2014;384:1164-1166.

19. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;CD006564.

20. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.

21. Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:216-224.

22. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson’s disease. Approaches to treatment. Drugs Aging. 2000;16:273-278.

23. Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82:914-923.

24. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomized placebo-controlled phase 3 trial. Lancet. 2014;383:533-540.

25. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. N Engl J Med. 2012;366:511-519.

26. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev. 2012;CD002817.

27. Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80:627-633.

28. Cronin H, Casey MC, Inderhaugh J, et al. Osteoporosis in patients with Parkinson’s disease. J Am Geriatr Soc. 2006;54:1797-1798.

29. Tan L, Wang Y, Zhou L, et al. Parkinson’s disease and risk of fracture: a meta-analysis of prospective cohort studies. PLoS One. 2014;9:e94379.

30. Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348-1352.

Parkinson’s disease (PD) can be a tough diagnosis to navigate. Patients with this neurologic movement disorder can present with a highly variable constellation of symptoms,¹ ranging from the well-known tremor and bradykinesia to difficulties with activities of daily living (particularly dressing and getting out of a car²) to nonspecific symptoms, such as pain, fatigue, hyposmia, and erectile dysfunction.³

Furthermore, medications more recently approved by the US Food and Drug Administration (FDA) have left many health care providers confused about what constitutes appropriate first-, second-, and third-line therapies, as well as add-on therapy for symptoms secondary to dopaminergic agents. What follows is a stepwise approach to managing PD that incorporates these newer therapies so that you can confidently and effectively manage patients with PD with little or no consultation.

First, though, we review who’s at greatest risk—and what you’ll see.

Family history tops list of risk factors for PD

While PD occurs in less than 1% of the population ≥40 years of age, its prevalence increases with age, becoming significantly higher by age 60 years, with a slight predominance toward males.⁴

A variety of factors increase the risk of developing PD. A well-conducted meta-analysis showed that the strongest risk factor is having a family member, particularly a first-degree relative, with a history of PD or tremor.⁵Repeated head injury, with or without loss of consciousness, is also a factor;⁵ risk increases with each occurrence.⁶ Other risk factors include exposure to pesticides, rural living, and exposure to well water.⁵

Researchers have conducted several studies regarding the effects of elevated cholesterol and hypertension on the risk of PD, but results are still without consensus.⁵ A study published in 2017 reported a significantly increased risk of PD associated with having hepatitis B or C, but the mechanism for the association—including whether it is a consequence of treatment—is unknown.⁷

Smoking and coffee drinking. Researchers have found that cigarette smoking, beer consumption, and high coffee intake are protective against PD,⁵ but the benefits are outweighed by the risks associated with these strategies.⁸ The most practical protective factors are a high dietary intake of vitamin E and increased nut consumption.⁹ Dietary vitamin E can be found in almonds, spinach, sweet potatoes, sunflower seeds, and avocados. Studies have not found the same benefit with vitamin E supplements.⁹